New York State Common Retirement Fund Decreases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

New York State Common Retirement Fund cut its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 7.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 150,198 shares of the biopharmaceutical company’s stock after selling 12,140 shares during the period. New York State Common Retirement Fund’s holdings in Regeneron Pharmaceuticals were worth $131,917,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. RWA Wealth Partners LLC purchased a new position in Regeneron Pharmaceuticals during the fourth quarter worth $375,000. MCF Advisors LLC boosted its stake in shares of Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 12 shares during the last quarter. Criterion Capital Advisors LLC purchased a new stake in Regeneron Pharmaceuticals during the 4th quarter worth about $37,000. Sumitomo Mitsui DS Asset Management Company Ltd raised its stake in Regeneron Pharmaceuticals by 6.4% in the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 12,811 shares of the biopharmaceutical company’s stock valued at $11,252,000 after purchasing an additional 766 shares during the last quarter. Finally, Signaturefd LLC raised its stake in Regeneron Pharmaceuticals by 2.6% in the 4th quarter. Signaturefd LLC now owns 2,126 shares of the biopharmaceutical company’s stock valued at $1,867,000 after purchasing an additional 54 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 0.5 %

Shares of NASDAQ:REGN traded up $4.15 during midday trading on Tuesday, hitting $904.31. 98,199 shares of the company’s stock traded hands, compared to its average volume of 488,133. Regeneron Pharmaceuticals, Inc. has a twelve month low of $684.80 and a twelve month high of $998.33. The company has a market cap of $99.26 billion, a PE ratio of 25.90, a P/E/G ratio of 2.58 and a beta of 0.11. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69. The firm’s fifty day moving average price is $952.07 and its two-hundred day moving average price is $892.70.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, topping analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The business had revenue of $3.43 billion for the quarter, compared to analysts’ expectations of $3.29 billion. During the same period in the previous year, the company posted $10.96 earnings per share. The business’s revenue for the quarter was up .6% compared to the same quarter last year. On average, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.8 EPS for the current fiscal year.

Insider Activity

In related news, Director Bonnie L. Bassler sold 827 shares of the business’s stock in a transaction dated Tuesday, January 30th. The stock was sold at an average price of $959.00, for a total value of $793,093.00. Following the transaction, the director now owns 1,382 shares in the company, valued at $1,325,338. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $954.22, for a total transaction of $95,422.00. Following the transaction, the director now owns 18,382 shares of the company’s stock, valued at $17,540,472.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bonnie L. Bassler sold 827 shares of the business’s stock in a transaction dated Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total value of $793,093.00. Following the completion of the sale, the director now directly owns 1,382 shares of the company’s stock, valued at $1,325,338. The disclosure for this sale can be found here. Insiders sold 11,022 shares of company stock worth $10,552,991 over the last ninety days. Corporate insiders own 8.83% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on REGN. Royal Bank of Canada reiterated an “outperform” rating and set a $1,189.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 9th. Sanford C. Bernstein started coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 target price on the stock. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Barclays lifted their price objective on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an “overweight” rating in a research report on Tuesday, January 23rd. Finally, UBS Group increased their target price on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a research report on Wednesday, April 17th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $976.41.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.